Danaher Corporation DHR · Stock Open Danaher Corporation in new tab

Shares fell 10.9% following the quarter as investors reacted negatively to cautious commentary around demand headwinds in developed markets, shipment timing disruptions, and continued margin pressure despite stable revenue growth.

• Reported sales of $6.3 billion with 3% core revenue growth year-over-year; core ex-respiratory testing up 4.5%, accelerating from Q1.
• Developed markets showed slight core revenue decline due to shipment timing issues in biotechnology and weaker respiratory revenue.
• High-growth markets expanded over 10%, including mid-single-digit growth in China driven by Cytiva partnerships.
• Life sciences and diagnostics segments remained stable but not enough to offset concerns about margin compression and commercial execution challenges in certain regions.
• Management maintained a cautiously optimistic outlook but signaled ongoing uncertainty around Biotechnology shipment timing and macroeconomic factors impacting developed regions.